The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Clinical significance of relative dose intensity during pazopanib treatment to advanced/metastatic soft tissue sarcoma (STS) patients.
 
Kenji Nakano
Consulting or Advisory Role - GlaxoSmithKline; Novartis
Speakers' Bureau - Eisai; Merck Serono; Novartis
Travel, Accommodations, Expenses - Merck Serono; Novartis
 
Yoshiya Sugiura
No Relationships to Disclose
 
Shinichiro Taira
No Relationships to Disclose
 
Junichi Tomomatsu
Employment - Eisai
 
Keiko Hayakawa
No Relationships to Disclose
 
Yuki Funauchi
No Relationships to Disclose
 
Tabu Gokita
No Relationships to Disclose
 
Taisuke Tanizawa
No Relationships to Disclose
 
Keisuke Ae
No Relationships to Disclose
 
Seiichi Matsumoto
No Relationships to Disclose
 
Shunji Takahashi
Stock and Other Ownership Interests - Novartis
Research Funding - Novartis